AI
CERO

Arena Investors’s CERo Therapeutics CERO Stock Holding History

Arena Investors’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$59.4K Buy
+99
New +$230K 0.47% 10

Other funds holding CERO

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
APP
Avantax Planning Partners Dubuque, Iowa $4.02B AUM 20% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Arena Investors's CERO Position: Q2 2024 in Review

Arena Investors opened a new position in CERo Therapeutics (CERO) in Q2 2024: 99 shares worth $59.4K. The stake represents 0.47% of the portfolio and ranks #10 among its holdings.

11 funds tracked by Wall St. Rank hold CERO as of Q2 2024.

  • Arena Investors held 99 shares of CERo Therapeutics worth $59.4K as of Q2 2024.
  • CERo Therapeutics was a new Arena Investors position in Q2 2024.
  • CERo Therapeutics made up 0.47% of Arena Investors's portfolio in Q2 2024, its #10 holding.
  • 11 funds tracked by Wall St. Rank held CERo Therapeutics as of Q2 2024.

Based on Arena Investors's 13F filing for Q2 2024, filed 14 Aug 2024.